Related Experiment Video
Updated: Jun 6, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Paraneoplastic syndromes in prostate cancer
Matthew K Hong1, Jennifer Kong, Benjamin Namdarian
1Division of Urology, Department of Surgery, University of Melbourne, Royal Melbourne Hospital, Grattan Street, Parkville, Melbourne, Victoria 3050, Australia. m.k.hong@ausdoctors.net
Nature Reviews. Urology
|December 9, 2010
Summary
Paraneoplastic syndromes, rare in prostate cancer, often signal advanced disease and can be the first sign of malignancy. Early recognition aids diagnosis and treatment, potentially improving outcomes for aggressive tumors.
Area of Science:
- Uro-oncology
- Oncology
- Endocrinology
Background:
- Paraneoplastic syndromes are rare but significant complications associated with malignancies.
- Prostate cancer is the second most common urological malignancy linked to paraneoplastic syndromes, following renal cell carcinoma.
- These syndromes often indicate advanced, aggressive prostate cancer with poor prognoses.
Observation:
- The literature documents approximately 100 cases of paraneoplastic syndromes in prostate cancer patients.
- Manifestations include endocrine, neurological, and dermatological conditions.
- Over 70% of cases present with the syndrome as the initial clinical sign of prostate cancer.
Findings:
- In under 20% of cases, paraneoplastic syndromes signal progression to castrate-resistant prostate cancer.
- The majority of reported cases involve advanced, metastatic malignancy.
- Syndromes typically resolve with prostate cancer treatment, though some require specific therapies.
Implications:
- Recognizing paraneoplastic syndromes is crucial for early cancer detection and guiding treatment strategies.
- Identifying serum markers and their presence in tumor tissue can strengthen the link between the syndrome and prostate cancer.
- Further research into the biology of these syndromes may elucidate the molecular mechanisms driving aggressive prostate cancer.
